Friday, 16 October 2026European Markets

HOTELS DE PARIS Stock Over 11% Up So Far On Thursday

Loading stream...

(vianews) - shares of hotels de paris (cac 40: hdp.pa) rose by a staggering 11.72% to €1.43 at 11:55 est on thursday, after three sequential sessions in a row of losses. cac 40 is dropping 0.61% to €7,284.08, after three sequential sessions in a row of gains. this seems, up to now, a somewhat negative trend trading session today.

about hotels de paris

les hôtels de paris sa operates and manages hotels in paris. as of december 31, 2021, it operated 17 hotels in paris, 1 hotel in st tropez, and 1 hotel in marrakech. the company was incorporated in 1992 and is headquartered in paris, france.

earnings per share

as for profitability, hotels de paris has a trailing twelve months eps of €-0.64.

volatility

hotels de paris's last week, last month's, and last quarter's current intraday variation average was a negative 5.72%, a positive 0.47%, and a positive 4.36%.

hotels de paris's highest amplitude of average volatility was 5.72% (last week), 4.04% (last month), and 4.36% (last quarter).

volume

today's last reported volume for hotels de paris is 390 which is 1.51% below its average volume of 396.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, hotels de paris's stock is considered to be overbought (>=80).

more news about hotels de paris (hdp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com